Market Briefing: Rate Hike Outlook and Record Corporate Profits
The IMF has lowered its global growth forecast, sparking concerns about its impact on the local economy. Meanwhile, Citi suggests a potential interest rate hike in July, with inflation expected to remain high through September. On the bright side, the top 1,000 listed companies just posted their strongest operating profits since 2000.
Market Briefing — April 15, 2026
Macroeconomic and Policy Trends
IMF Lowers Global Growth Forecast
On April 14, 2026, the IMF released its World Economic Outlook, cutting its global growth projections. Analysts are now closely monitoring how this shift will affect an export-heavy economy.
Bank of Korea Eyes July Rate Hike; Inflation Seen at 2.8–3.3%
A report from Citibank suggests the Bank of Korea might begin raising interest rates this July, with inflation expected to hover between 2.8% and 3.3% through September. The report notes, however, that a prolonged blockade of the Strait of Hormuz could delay this timeline.
Won/Dollar Exchange Rate Hovers Near 1,500
The KRW/USD exchange rate is fluctuating around the 1,500 mark—levels not seen since the 2008 global financial crisis. While experts don't necessarily view this as a sign of an imminent economic collapse, they caution that market anxiety is clearly on the rise.
Market Recovery Follows US-Iran Truce
North American markets saw a complex mix of events on April 13, including geopolitical tensions in the Middle East, oil price volatility, and a strong rebound in US stocks. Locally, the market has been rallying since the two-week ceasefire agreement between the US and Iran was reached on the 8th.
Key Corporate News
Top 1,000 Companies Post Record Profits Since 2000
Last year, the top 1,000 listed companies reported nearly 190 trillion won in operating profit—the highest figure since 2000. The number of companies in the "1 trillion won profit club" has also hit an all-time high, driven largely by the recovery of major semiconductor and export-focused firms.
FSS to Overhaul Pharma/Biotech Disclosure Rules
The Financial Supervisory Service (FSS) is revamping disclosure rules for pharma and biotech companies to better protect investors. The move follows concerns over the gap between high valuations based on licensing expectations and actual cash flow, which has caused significant volatility in KOSDAQ biotech stocks.
Today’s IR Schedule: Nongshim, Global Tax Free, TLB, and More
Key investor relations (IR) sessions for April 15 include presentations from Dongbang Medical, TLB (discussing rights offerings and status updates), and ISU Specialty Chemical.
Market Analysis and Outlook
① KOSPI Targets 6,000, but "Double-Listing Illusion" Persists
Analysts warn that the KOSPI’s push toward the 6,000-point mark may be partially inflated by the "optical illusion" created by double-listed stocks, making it difficult to gauge the true strength of the market recovery.
② Recovery Speed After Middle East Tensions
The local market saw some of the world's steepest declines following the Middle East conflict, and now all eyes are on the speed of the recovery. With the US-Iran truce in place, investors are watching to see if the market can retake its previous highs.
③ Triple Headwinds: Growth Cuts, FX Volatility, and Rate Hikes
The market is currently navigating a "triple threat": the IMF’s lowered growth forecast, the weak KRW hovering at 1,500, and the potential for a July rate hike. Despite these pressures, the fundamental strength of corporate earnings suggests a tug-of-war in market sentiment ahead.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
